Literature DB >> 28400520

Reply to Marchiò et al.: Antitumor immune regulation by angiostatic therapy.

Madelon Q Wentink1, Elisabeth J M Huijbers1, Peter Timmerman2,3, Arjan W Griffioen4.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28400520      PMCID： PMC5402420          DOI： 10.1073/pnas.1703074114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  11 in total

1.  Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium.

Authors:  A W Griffioen; C A Damen; G H Blijham; G Groenewegen
Journal:  Blood       Date:  1996-07-15       Impact factor: 22.113

Review 2.  Vaccination approach to anti-angiogenic treatment of cancer.

Authors:  Madelon Q Wentink; Elisabeth J M Huijbers; Tanja D de Gruijl; Henk M W Verheul; Anna-Karin Olsson; Arjan W Griffioen
Journal:  Biochim Biophys Acta       Date:  2015-01-30

3.  Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity.

Authors:  Madelon Q Wentink; Tilman M Hackeng; Sebastien P Tabruyn; Wouter C Puijk; Klaus Schwamborn; Daniele Altschuh; Rob H Meloen; Teun Schuurman; Arjan W Griffioen; Peter Timmerman
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-17       Impact factor: 11.205

4.  Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer.

Authors:  Ruud P M Dings; Kieng B Vang; Karolien Castermans; Flavia Popescu; Yan Zhang; Mirjam G A Oude Egbrink; Matthew F Mescher; Michael A Farrar; Arjan W Griffioen; Kevin H Mayo
Journal:  Clin Cancer Res       Date:  2011-01-20       Impact factor: 12.531

5.  The revival of cancer vaccines - The eminent need to activate humoral immunity.

Authors:  Elisabeth J M Huijbers; Arjan W Griffioen
Journal:  Hum Vaccin Immunother       Date:  2017-01-24       Impact factor: 3.452

6.  Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors.

Authors:  Anita E M Dirkx; Mirjam G A oude Egbrink; Karolien Castermans; Daisy W J van der Schaft; Victor L J L Thijssen; Ruud P M Dings; Lucy Kwee; Kevin H Mayo; John Wagstaff; Jessica C A Bouma-ter Steege; Arjan W Griffioen
Journal:  FASEB J       Date:  2006-04       Impact factor: 5.191

7.  Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression.

Authors:  Anita E M Dirkx; Mirjam G A Oude Egbrink; Marijke J E Kuijpers; Sandra T van der Niet; Viviane V T Heijnen; Jessica C A Bouma-ter Steege; John Wagstaff; Arjan W Griffioen
Journal:  Cancer Res       Date:  2003-05-01       Impact factor: 12.701

8.  Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo.

Authors:  D Gabrilovich; T Ishida; T Oyama; S Ran; V Kravtsov; S Nadaf; D P Carbone
Journal:  Blood       Date:  1998-12-01       Impact factor: 22.113

9.  Fingerprinting the circulating repertoire of antibodies from cancer patients.

Authors:  Paul J Mintz; Jeri Kim; Kim-Anh Do; Xuemei Wang; Ralph G Zinner; Massimo Cristofanilli; Marco A Arap; Waun Ki Hong; Patricia Troncoso; Christopher J Logothetis; Renata Pasqualini; Wadih Arap
Journal:  Nat Biotechnol       Date:  2002-12-23       Impact factor: 54.908

Review 10.  Anti-angiogenesis: making the tumor vulnerable to the immune system.

Authors:  Arjan W Griffioen
Journal:  Cancer Immunol Immunother       Date:  2008-04-26       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.